Scarica l'app Stockscreener
63.66
0.16%
0.10
Dopo l'orario di chiusura:
63.45
-0.21
-0.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Is Halozyme Therapeutics (HALO) Pricing Look Interesting After Recent Share Price Volatility - simplywall.st
Halozyme Therapeutics Receives 'Hold' Rating from Analysts - National Today
Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness - Yahoo Finance
Halozyme Therapeutics (HALO) Valuation Check After Recent Share Price Pullback - simplywall.st
Halozyme names David Ramsay as interim CFO By Investing.com - Investing.com India
Halozyme names David Ramsay as interim CFO - Investing.com South Africa
Halozyme Taps David Ramsay as Interim Chief Financial Officer - Contract Pharma
Halozyme Names David Ramsay Interim Chief Financial Officer - TipRanks
Halozyme Therapeutics, Inc. Appoints David Ramsay as Interim Chief Financial Officer, Effective March 23, 2026 - marketscreener.com
Halozyme (HALO) Appoints David Ramsay as Interim CFO - GuruFocus
Halozyme (HALO) Appoints Interim CFO Amid Search for Permanent E - GuruFocus
Halozyme Appoints David Ramsay as Interim Chief Financial Officer - PR Newswire
Capital Fund Management Boosts Stake in Halozyme Therapeutics - National Today
Capital Fund Management S.A. Has $15.60 Million Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme at Citizens Life Sciences: Strategic Growth and Innovations By Investing.com - Investing.com Nigeria
Halozyme at Citizens Life Sciences: Strategic Growth and Innovations - Investing.com
Insider Selling: Cortney Caudill Unloads $1.96M Of Halozyme Therapeutics Stock - Benzinga
Halozyme Therapeutics, Inc. $HALO Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Halozyme Therapeutics COO Sells $599,000 in Shares - National Today
Halozyme Therapeutics (NASDAQ:HALO) COO Cortney Caudill Sells 8,857 Shares - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) COO Sells 20,000 Shares of Stock - MarketBeat
Halozyme at Leerink Conference: Strategic Advances in Drug Delivery By Investing.com - Investing.com Canada
Halozyme at Leerink Conference: Strategic Advances in Drug Delivery - Investing.com
Halozyme (HALO) COO exercises 21,546 options and sells 28,857 shares - Stock Titan
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - GlobeNewswire Inc.
Rule 144 sale notice: HALO (NASDAQ: HALO) 20,000 shares via option exercise - Stock Titan
Neo Ivy Capital Management Reduces Stake in Halozyme Therapeutics - National Today
Neo Ivy Capital Management Cuts Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
DLD Asset Management LP Has $2.20 Billion Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Victory Capital Management Trims Halozyme Therapeutics Stake - National Today
Victory Capital Management Inc. Sells 46,430 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? - MSN
Halozyme Therapeutics Says Johnson & Johnson Wins FDA Approval for Blood Cancer Treatment - marketscreener.com
Drug combo for relapsed or refractory myeloma cuts progression or death risk 83% - Stock Titan
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case - ChartMill
Did Record ENHANZE Royalties and New Deals Just Shift Halozyme Therapeutics' (HALO) Investment Narrative? - Sahm
Snyder Capital Management L P Sells 663,853 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Shares Sold by Investment Firm - National Today
Halozyme Therapeutics, Inc. $HALO Shares Sold by GW&K Investment Management LLC - MarketBeat
Cresset Asset Management LLC Reduces Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,393,800.00 in Stock - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 10,000 Shares of Stock - MarketBeat
Is Halozyme Therapeutics (HALO) Pricing Reflect Long Term Prospects After Recent Share Pullback - Yahoo Finance
Halozyme Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo
Halozyme Therapeutics (HALO) Valuation Check As Recent Share Pullback Follows Strong Multi Year Returns - Yahoo Finance
Segall Bryant & Hamill LLC Sells 94,261 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Fisher Asset Management Boosts Stake in Halozyme Therapeutics - National Today
Fisher Asset Management LLC Purchases 29,147 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALO Earnings History & Surprises | EPS & Revenue Results | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme at TD Cowen Health Care Conference: Strategic Growth Insights - Investing.com
Halozyme Therapeutics (HAM:RV7) Total Operating Expense : €318 Mil (TTM As of Dec. 2025) - GuruFocus
Halozyme Therapeutics Sees Increased Investment from Handelsbanken Fonder AB - National Today
Halozyme Therapeutics (HAM:RV7) Investments And Advances : €0 Mil (As of Dec. 2025) - GuruFocus
Halozyme Therapeutics Stock Holdings Reduced by Rafferty Asset Management - National Today
Halozyme Therapeutics, Inc. $HALO Stock Holdings Lessened by Rafferty Asset Management LLC - MarketBeat
Halozyme Acquisitions And ENHANZE Growth Shape Long Term Valuation Story - Sahm
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unlocking A 21.53% Potential Upside - DirectorsTalk Interviews
Halozyme Therapeutics (HAM:RV7) Ending Cash Position : €117 Mil (As of Dec. 2025) - GuruFocus
Why Halozyme Therapeutics (HALO) Is Up 8.1% After Raising 2026 Revenue Guidance to up to $1.81 Billion - Sahm
Halozyme Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
A Look At Halozyme Therapeutics (HALO) Valuation After Recent Share Price And Licensing Momentum - simplywall.st
Is Halozyme Therapeutics (HALO) a Buy Post Earnings? - Finviz
Artisan Partners Limited Partnership Sells 752,150 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HAM:RV7) Preferred Stock : €0 Mil (As of Dec. 2025) - GuruFocus
12 Cheap Biotech Stocks to Buy Now - Insider Monkey
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):